346 related articles for article (PubMed ID: 19424611)
1. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
2. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
[TBL] [Abstract][Full Text] [Related]
3. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
[TBL] [Abstract][Full Text] [Related]
4. Expression of drs mRNA in human lung adenocarcinomas.
Shimakage M; Takami K; Kodama K; Mano M; Yutsudo M; Inoue H
Hum Pathol; 2002 Jun; 33(6):615-9. PubMed ID: 12152160
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
6. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of drs mRNA in human colon adenocarcinomas.
Shimakage M; Kawahara K; Kikkawa N; Sasagawa T; Yutsudo M; Inoue H
Int J Cancer; 2000 Jul; 87(1):5-11. PubMed ID: 10861446
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of drs mRNA in human prostate carcinomas.
Kim CJ; Shimakage M; Kushima R; Mukaisho K; Shinka T; Okada Y; Inoue H
Hum Pathol; 2003 Jul; 34(7):654-7. PubMed ID: 12874760
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
Yeh YC; Chou TY
J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
14. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
[No Abstract] [Full Text] [Related]
15. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung.
Nasgashio R; Sato Y; Matsumoto T; Kageyama T; Hattori M; Iyoda A; Satoh Y; Ryuge S; Masuda N; Jiang SX; Saegusa M
Lung Cancer; 2011 Dec; 74(3):405-10. PubMed ID: 21601304
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
17. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
[TBL] [Abstract][Full Text] [Related]
19. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
20. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
